These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 22096922)

  • 1. [Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them].
    Iwasaki Y; Ikeda F; Yamamoto K
    Nihon Rinsho; 2011 May; 69 Suppl 4():215-20. PubMed ID: 22096922
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin.
    Ennaifer R; Cheikh M; Romdhane H; Hefaiedh R; Ben Nejma H; Bel Hadj N
    Tunis Med; 2014 Jan; 92(1):42-3. PubMed ID: 24879173
    [No Abstract]   [Full Text] [Related]  

  • 3. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
    Slim J; Afridi MS
    Infect Dis Clin North Am; 2012 Dec; 26(4):917-29. PubMed ID: 23083824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pegylated intereferon hematological safety in comparison with standard].
    Fazylov VKh; Manapova ÉR; Tkacheva SV; Sozinova IuM
    Eksp Klin Gastroenterol; 2012; (6):96-9. PubMed ID: 23402198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinal vein thrombosis associated with peginterferon alpha 2b plus ribavirin in a chronic hepatitis C patient.
    Such Díaz A; Barrueco N; Esteban Alba C; Escobar Rodríguez I
    Farm Hosp; 2011; 35(2):93-4. PubMed ID: 20615736
    [No Abstract]   [Full Text] [Related]  

  • 7. Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy.
    Jain S; Midha V; Sood A
    Indian J Gastroenterol; 2011 Sep; 30(5):239-40. PubMed ID: 21986854
    [No Abstract]   [Full Text] [Related]  

  • 8. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
    [No Abstract]   [Full Text] [Related]  

  • 9. Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report.
    Verma P; Dayal S; Jain VK; Amrani A
    J Chemother; 2017 Dec; 29(6):380-382. PubMed ID: 27741937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of irreversible leukoencephalopathy in a patient with C virus hepatitis treated with pegylated interferon-alpha-2b and ribavirin.
    Iacob SA; Petrescu AM; Iacob DG
    Rom J Intern Med; 2013; 51(3-4):197-200. PubMed ID: 24620633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Side effects of therapy for chronic hepatitis C.
    Russo MW; Fried MW
    Gastroenterology; 2003 May; 124(6):1711-9. PubMed ID: 12761728
    [No Abstract]   [Full Text] [Related]  

  • 12. [Antiviral therapy for chronic viral hepatitis B and C].
    Iino S
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():787-91. PubMed ID: 12722317
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hepatitis C infection. Overweight virus carriers are more difficult to cure].
    MMW Fortschr Med; 2004 Mar; 146(13):58. PubMed ID: 15219135
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
    Burgueño-Montañés C; Pérez-Álvarez R
    Arch Soc Esp Oftalmol; 2011 Jun; 86(6):193-5. PubMed ID: 21767697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
    Abellán Galiana P; Pérez-Lázaro A; Aguilera Sancho-Tello V; Merino Torres JF; Berenguer Haym M; Piñón Sellés F
    Endocrinol Nutr; 2009 Mar; 56(3):136-9. PubMed ID: 19627727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of hepatitis C treatments: Need for a comprehensive evaluation.
    DeNardo Z; Choi M; Stiller M; Buechel D
    Kaohsiung J Med Sci; 2017 Nov; 33(11):584-585. PubMed ID: 29050677
    [No Abstract]   [Full Text] [Related]  

  • 17. [Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin: case report and literature review].
    Cacopardo B; Pinzone MR; Nunnari G
    Infez Med; 2013 Mar; 21(1):40-44. PubMed ID: 23524900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
    Klimacka-Nawrot E; Musialik J; Suchecka W; Petelenz M; Hartman M; Lichtański P; Błońska-Fajfrowska B
    Wiad Lek; 2010; 63(4):289-99. PubMed ID: 21608370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cutaneous necrosis due to injection of interferon-alpha 2b in a patient with chronic hepatitis C].
    Castellanos González M; Pérez Carreras M; Muñoz Gómez R; Castellano Tortajada G
    Gastroenterol Hepatol; 2011 Oct; 34(8):584-5. PubMed ID: 21641684
    [No Abstract]   [Full Text] [Related]  

  • 20. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    Onyike CU; Bonner JO; Lyketsos CG; Treisman GJ
    Am J Psychiatry; 2004 Mar; 161(3):429-35. PubMed ID: 14992966
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.